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ABSTRACT
The risk of developing neurodegenerative disorders such as Alzheimer’s disease 
(AD) increases dramatically with age. Understanding the underlying mechanisms of 
brain aging is crucial for developing preventative and/or therapeutic approaches for 
age-associated neurological diseases. Recently, it has been suggested that epigenetic 
factors, such as histone modifications, maybe be involved in brain aging and age-
related neurodegenerations. In this study, we investigated 14 histone modifications 
in brains of a cohort of young (3 months), old (22 months), and old age-matched 
dietary restricted (DR) and rapamycin treated BALB/c mice. Results showed that 7 
out of all measured histone markers were changed drastically with age. Intriguingly, 
histone methylations in brain tissues, including H3K27me3, H3R2me2, H3K79me3 
and H4K20me2 tend to disappear with age but can be partially restored by both DR 
and rapamycin treatment. However, both DR and rapamycin treatment also have a 
significant impact on several other histone modifications such as H3K27ac, H4K16ac, 
H4R3me2, and H3K56ac, which do not change as animal ages. This study provides 
the first evidence that a broad spectrum of histone modifications may be involved in 
brain aging. Besides, this study suggests that both DR and rapamycin may slow aging 
process in mouse brain via these underlying epigenetic mechanisms.
INTRODUCTION
In industrialized countries, life expectancy is rapidly 
rising, and this has led to an increasing incidence of age-
related neurodegenerative disorders including Alzheimer’s 
disease (AD), Parkinson disease (PD) and Huntington 
Disease (HD). The lack of effective therapies that can 
halt and/or reverse the progression of these disorders 
creates an enormous burden on both affected individuals 
and society as a whole. Developing preventative or 
therapeutic interventions for such conditions demands 
deeper understanding of the processes underlying normal 
brain aging [1-2]. Brain aging is marked by a gradual 
decline in cognitive function, which is often correlated 
with age-dependent deterioration of synaptic function 
in brain regions crucial for memory formation and 
consolidation, such as the hippocampus and prefrontal 
cortex [3-4]. The neurobiological processes underlying 
these age-related learning and memory deficits include 
aberrant changes in gene transcription that eventually 
affects the plasticity of the aged brain. Changes in gene 
expression in neurons were thought to take place during 
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brain aging, and analysis of regions of the hippocampus 
and front cortex by microarray has confirmed this [5-7]. 
The molecular mechanisms underlying these changes in 
gene expression and the regulation are largely unknown, 
but recent studies point to a novel possibility that the 
dysregulation of epigenetic control of gene expression 
may be involved [8-10]. 
The term “epigenetics” was first coined by Conrad 
Waddington in the 1940s to describe interactions of genes 
with their environment during development stages [11]. 
The first suggestion that DNA methylation might play 
an important biological role was made by Griffith and 
Mahler in 1969 indicating that it could provide a basis 
for long term memory in the brain [12]. The two most 
widely studied epigenetic codes are DNA methylation 
and histone modifications. Epigenetic regulation is a key 
transcriptional mechanism that alters gene expression by 
altering the structure and/or conformation of chromatin but 
does not change the basic genetic code. Many fundamental 
cellular processes are affected by epigenetic modulation, 
and it has become evident that chromatin-based 
epigenetic mechanisms underlie important aspects of 
the aging process. Recent reports indicate that chromatin 
remodeling via histone acetylation plays a crucial role in 
regulating synaptic and cognitive function in aging and 
neurodegenerative brains [13-16]. Increasing histone 
acetylation by inhibition of histone deacetylase (HDAC) 
enhances gene transcription and improves hippocampal 
long-term potentiation (LTP) or memory functions in 
several experimental models of neurological diseases [17-
19], indicating that dysregulation of chromatin acetylation 
may be involved in certain forms of cognitive impairment 
[20-21]. Histone methylation can occur on either lysine 
(K) or arginine (R) residues, and can be mono-, di- or 
trimethylated, and either activation or repression is 
dependent upon the particular histone residue, that is 
modified [22-23]. Therefore, identifying new histone 
modifications that may be involved in brain aging has a 
potential to provide critical insights into the neurobiology 
of aging and possibly the etiology of neurodegenerative 
disorders. 
Dietary restriction (DR) delays aging and improves 
resistance to disease in a fashion that is evolutionarily 
conserved from yeast to primates and humans [24-25], 
though controversy was stirred lately on an NIH-initiated 
primate cohort study [26]. These beneficial effects 
include, in mammals, the attenuation of age-associated 
cognitive impairment and neurodegeneration [27-28]. 
More specifically, synaptic plasticity was shown to be 
enhanced by DR, as evidenced by increased LTP [29]. 
rapamycin, an antibiotic, is already in use for suppressing 
the immune system in transplant patients and has been 
used in the treatment of certain cancers for decades. 
Lately rapamycin treatment produced remarkable effect 
of extending lifespan even though it was not started until 
the mice had lived 600 days - equivalent to human being 
aged 60 years [30]. A similar benefit on lifespan has also 
been observed when started on the drug at a younger age 
(9 months old) [31]. Blagosklonny discussed the link 
between aging and diseases by rapamycin treatment [32]. 
Moreover, Rapamycin has been found to have the potential 
for reversing some of the effects of premature aging [33]. 
Interestingly, rapamycin treatment suppresses brain aging 
in senescence-accelerated OXYS rats [34] and results 
in an improvement in cognitive functions that normally 
decline with age in mice [35-36]. Furthermore, inhibition 
of mTOR by rapamycin can slow or block AD progression 
in a transgenic mouse model of the disease [37]. 
Finally, epigenetic factors are not only inheritable 
but also reversible. Thus, these factors, such as histone 
acetylation and methylation, may participate in the 
modulation of cell plasticity in responses to environmental 
cues in the brain. It is of great interest to hypothesize 
that intervention approaches such as DR and rapamycin 
administration, which not only extending the lifespan 
of animals under certain conditions but also promote 
certain brain functions in mice, may impact some age-
induced post-translational modifications of histones. In the 
present study, we aim to test this hypothesis by examining 
expression of a panel of 14 histone modifications in brains 
of a mouse cohort in which the mice were maintained for 
over 2 years either eating ad libitum, or with either DR or 
rapamycin treatment. 
RESULTS
To identify the histone modifications which either 
change with age and/or respond to age-interventions 
including DR and rapamycin treatment in mouse brain, a 
cohort of BALB/c mice with groups of young (3 months), 
old (22 months), old age-matched DR, and old age-
matched rapamycin treatment and a panel of 14 histone 
antibodies against specific methylations or acetylations 
in residues of both lysine (K) and arginine (R) were 
applied in this study (Table 1). Surprisingly, over 50% of 
detected histone modifications in brains from these mice 
were altered as a result of the age of animals or the age-
interventions. Interestingly, those modifications have not 
been reported to be associated with brain aging or age-
interventions until now. 
Among the measured histone modifications, the 
levels of H3K27me3, H3R2me2 and H3K79me3 in brains 
of old (22 months) mice were reduced to 68% (p < 0.01), 
83% (p < 0.05) and 67% (p < 0.05) respectively when 
compared to 3-month old animals. However, both DR and 
rapamycin treatment prevented the age-induced losses of 
H3K27me3, H3R2me2 and H3K79me3. Specifically, DR 
restored the levels of these histones of old age group to 
92.5%, 132% and 104% of young age group, respectively, 
and likewise, rapamycin exhibited an even stronger impact 
by increasing the levels of these histone methylations 
to 133%, 132% and 120% of those seen in the young 
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age group (Figure 1A-1C). Interestingly, the level of 
H4K20me2 is increased with age (159%, p < 0.05) when 
in mice on DR, this was reduced to 108%. Rapamycin 
treatment, contrary to DR, was unable to suppress the age-
induced H4K20me2 expression (Figure 1D). 
In addition, levels of H3K18ac, H3K4me2 and 
H3K4me were also changed with brain aging (Figure 2 
A-C). The levels of H3K18ac and H3K4me2 increased 
44% (p < 0.05) and 29% (p < 0.01), respectively, and the 
level of H3K4me decreased 32% (p < 0.01) in old brains 
when compared to that of young brains. The levels of 
H3K18ac and H3K4me2 were enhanced further by DR 
(76%, p < 0.05 and 44%, p < 0.01, respectively) and 
rapamycin (77%, p < 0.01 and 16%, p < 0.05, respectively) 
when compared to the old group. Furthermore, the level of 
H3K4me declined with age and was further diminished 
by both DR and rapamycin (51% and 70%, p < 0.01, 
respectively), when compared with the old group. 
Both DR and rapamycin also demonstrated 
unique functions in modulating the expression of 
histone modifications that do not respond to age. Four 
transcriptional activation histone modifications, H3K27ac, 
H4K16ac, H4R3me2 and H3K56ac, do not shown 
detectable differences between young and old brains, but 
Figure 1: Histone methylations are changed with age but the age-associated change is prevented by DR and/or 
rapamycin treatment in mouse brain. Representative western blots (upper) and quantitative densitometric analysis (lower) of 
H3K27me3 A., H3R2me2 B., H3K79me3 C. and H4K20me2 D. in brains from 3 months old ad libitum (Young), 22 months old ad libitum 
(Old) , 22 months old dietary restricted (DR) and 22 months old rapamycin treatment (RAL) BALB/c mice. Histone modification levels 
were normalized to total H3 content. The values (mean±S.E.M.) are expressed as a percentage relative to the 3 months old group. n = 3~5 
animals per goup . (**p < 0.01, *p < 0.05 Old versus Young, DR versus Old, RAL versus Old).
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their expression was changed significantly by DR and/or 
rapamycin treatment (Figure 2D-2G). Compared to the 
age-matched controls, both DR and rapamycin treatment 
increased the expression of 37% and 54%, respectively 
of H3K27ac (p < 0.05); DR alone decreased expression 
of H4K16ac to 69% (p < 0.05). Rapamycin increased 
expression of H4R3me2 to 188% but decreased the 
expression of H3K56ac over 10 times (p < 0.05). 
DISCUSSION
The organization of the eukaryotic genome 
into chromatin enables DNA to fit inside the nucleus. 
Essentially, histone proteins form a “spool” which 
allows DNA to be wound around them. Post-translational 
modification of histones has an effect on the tightness of 
DNA winding; it thus regulates the the accessibility of 
proteins such as transcriptional activators/repressors to 
Figure 2: Distinctive impact of DR and/or rapamycin treatment on histone modifications in mouse brain. Representative 
western blots (upper) and quantitative densitometric analysis (lower) of H3K18ac A., H3K4me2 B., H3K4me C., H3K27ac D., H4K16ac 
E., H4R3me2 F. and H3K56ac G. in brains from 3 months old ad libitum (Young), 22 months old ad libitum (Old) , 22 months old dietary 
restricted (DR) and 22 months old rapamycin treatment (RAL) BALB/c mice. Histone modification levels were normalized to total H3 
content. The values (mean±S.E.M.) are expressed as a percentage relative to the 3 months old group. n = 3~5 animals per goup . (**p < 
0.01, *p < 0.05 Old versus Young, DR versus Old, RAL versus Old).
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the DNA to facilitate genomic functions by turning on 
and off of gene expression. Tight winding keeps genes 
switched off, while loosening the packaging allows gene 
to be turned on. Therefore, remodeling of chromatin by 
histone modifications, such as acetylation, methylation 
and phosphorylation, is a key mechanism in controlling 
gene transcription in a variety of important biological 
processes [38]. 
Recent work suggests that histone acetylation has 
a critical role in age-associated declines in cognitive 
functions. Rodents exhibit a transient increase in histone 
acetylation after exposure to different learning paradigms 
[9]. Restoration of the expression of H4K12ac in mouse 
brain leads to a recovery of cognitive functions [16]. 
More importantly, rodents, after treatment with histone 
deacetylase inhibitors (HDACis), have demonstrated that 
Figure 3: Experimental design. A cohort of BALB/C mice were subjected to ad libitum, Dietary restriction and rapamycin at various 
time points.
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targeting histone acetylation has emerged as a promising 
strategy for therapeutic intervention in age-related 
cognitive function decline and neurodegenerative diseases 
[17, 39]. 
Histone methylation is another important and 
widespread type of chromatin modification that is 
known to influence biological processes in the context 
of development and cellular responses [21]. Histone 
methylation can occur on either lysine (K) or arginine (R) 
residues, and these can be mono-, di- or trimethylated, 
and either activation or repression is dependent upon the 
particular lysine residue that is modified [21]. For instance, 
H3K4me3, an active mark for transcription, is upregulated 
in hippocampus one hour following contextual fear 
conditioning [40]. Interestingly, a line of exciting evidence 
indicates that specific histone methylations, H3K4me3 
and H3K27me3, may act as a regulator of lifespan was 
confirmed by studies in C. elegans [41-42]. In addition, 
studies have shown that the expression of p16INK4a, a 
cell-cycle regulatory protein and an aging biomarker, can 
be regulated by H3K27me3 during cellular senescence 
[43]. However, whether histone methylation is involved 
in brain aging is still an open question. Encouragingly, we 
identified alterations in the methylation level of several 
hisotone residues including H3K27me3, H3R2me2, 
H3K79me3 and H4K20me2 with aging of mouse 
brains (Figure 1). The arginine residue methylation of 
Histone 3, H3R2me2, has never been associated with 
any brain function previously. More interestingly, these 
age-associated alterations are prevented by DR and/or 
rapamycin treatment (Figure 1). However, further work 
needs to be done to (1) study the functional significance 
of these histone changes in mouse brain aging, and (2) 
identify the transcriptional targets of these age-associated 
histone markers in neuronal cells. 
Brain aging and its direct consequences, such as 
degenerative diseases and even death, are inevitable; 
however, scientific advances in understanding basic 
aging mechanisms have made it much more feasible 
to postpone aging processes and to increase the animal 
lifespan using some specific regimens including DR 
and rapamycin administration. DR has been studied for 
decades in extending lifespans across species but the 
underlying molecular mechanism is not fully clear yet 
[24, 27]. Rapamycin, a bacterial product first isolated 
from soil on Easter Island, is the first drug intervention 
to reliably increase mammalian lifespan by 10% or more 
[30-31]. More intriguingly, Kolosova et. al. first described 
that rapamycin prevents brain aging in rat [34]; rapamycin 
also produces an improvement in age-associated cognitive 
functions in mouse[35-37]. We therefore wondered if 
epigenetic modifications play a role in mediating the 
beneficial effects of both DR and rapamycin in mouse 
brain aging. The results from our study unexpectedly 
exhibited that both DR and rapamycin can restore, at least 
partially, the age-related alterations in histone methylation 
levels (Figure 1). This may put forward a novel epigenetic 
mechanism of beneficial age-interventions. However, it is 
still not known whether these epigenetic responses have 
any relevance with the classic DR-driven IGF/Insulin 
and rapamycin-driven mTOR pathways in the brain. In 
addition, age and DR or rapamycin exhibit similar effects 
on the overall level of several histone modifications, 
such as H3K18ac, H3K4me2 and H3K4me (Figure 2A-
2C). It implies that those histone modifications may 
play dual regulatory roles in mediating both age and 
age-interventions. One possible favorable explanation 
is that age-adaptive cellular stress responses could be 
enhanced by DR and/or rapamycin to strengthen neuronal 
networks and plasticity [44]. Our study also showed that 
histone modifications such as H4K16ac and H3K56ac 
were stable with age but regulated by DR or rapamycin 
treatment (Figure 2D-2G). Interestingly, H4K16ac has 
been identified as DR regulated histone marker that may 
be modulated by Sirt1 regulation [45]. H3K56ac has also 
been identified biochemically as a direct target of mTOR 
inhibition by a chemical genomic screening recently [46]. 
The latter suggests a novel chromatin-regulating role for 
mTOR signaling. 
In summary, this study has examined a panel of 
histone modifications in mouse brain, and different 
patterns of histone modifications are responsive to 
normal aging and age-interventions including DR and 
rapamycin treatment. Based on these findings, we 
propose that dysregulation of chromatin remodeling may 
occur and contribute to brain aging as well as cognitive 
impairments observed in age-related neurodegenerative 
diseases such as AD. Promising interventions targeting 
age-related conditions may prevent the associated change 
of histone modifications or bypass age-induced cognitive 
deficit with compensational pathways. We know that a 
large amount of careful work needs to be carried out in 
the future uncover the functional significance of these 
promising histone modifications. We hope this study 
offers enriched epigenetic information to brain aging and 
neurodegeneration researchers and encourages the field to 
consider and understand the role of epigenetic regulation 
in neuroplasticity and cognitive function. 
MATERIALS AND METHODS
Animals
BALB/C female mice were produced and 
maintained at the Jackson Laboratory (Bar Harbor, ME). 
At weaning (3 weeks of age), they were housed 4 per box 
in weaning cages. These cages were assigned to one of 3 
feeding regimens using Purina LabDiet’s 5LG6 irradiated 
formulation of the NIH-31 (4% fat) diet. Groups of ad 
libitum (AL) fed mice, both young (3 months) and old 
Oncotarget15888www.impactjournals.com/oncotarget
(22 months), were given uninhibited access to grain. A 
Group of DR mice were fed with 70% of the AL feeding 
rate after weaning and continued lifelong (22 months of 
age). For group of rapamycin-treated mice, the rapamycin 
was encapsulated, and 2.24 mg of rapamycin per kg 
body weight/day was administered (equivalent to AL 
feeding) for 3 months starting when the animals were 19 
months of age [30]. All procedures were carried out as 
indicated in Figure 3 and approved by the animal care 
and use committee of the Jackson Laboratory, and staff 
veterinarians monitored mice on a regular basis, finding 
no pathogens.
Tissues preparation
Mice were sacrificed by cervical dislocation 
according to the approved protocol. Then the health status 
of mice was first checked anatomically. The whole brains 
including all major parts of the brain of all mice without 
liver/kidney problems, severe inflammations’    or tumors 
that could impact brain health (e.g., pituitary tumors) were 
dissected out and snap frozen in liquid nitrogen, ground 
into powder with mortar and pestle in liquid nitrogen and 
then stored at -80°C. 
Acid extraction of histones
Core histone proteins were extracted from the mouse 
whole brain samples using an acid extraction method 
as described by Shechter et al. with slight modifications 
[47]. Briefly, all procedures were performed on ice, and all 
solutions were chilled to 4°C before use unless otherwise 
indicated. All centrifugation steps were performed at 
4°C. Thirty to sixty microgram whole brain powder was 
homogenized in ice-cold PBS containing the following: 
1mM phenylmethylsulfonyl fluoride, 1x complete protease 
inhibitor cocktail (Roche, cat. no. 1697498), 5mM sodium 
butyrate (Sigma-Aldrich, B5887). The homogenates 
were centrifuged at 1000g for 10min and the supernatant 
was discarded. The pellet was then resuspended in 1 ml 
hypotonic lysis buffer (10mM Tris-Cl pH 8.0, 1 mM KCl, 
1.5 mM MgCl2, 1 mM DTT), incubated for 30 min on 
rotator at 4°C, centrifuged at 14,000g for 10 min, and the 
supernatant (cytoplasmic fraction) was aspirated. The 
pellet (nuclear fraction) was then resuspended in 0.5 ml 
of 0.4N H2SO4, incubated for 30 min to overnight and 
centrifuged at 16,000g for 10 min. The supernatant was 
transferred to a fresh tube, and proteins were precipitated 
with acetone. Acid extracted histone proteins were then 
collected by centrifugation at 16,000g for 10 min. The 
supernatant was discarded, and the protein pellet was 
washed with acetone. The resulting purified histone 
proteins were resuspended in deionized water and stored 
at -80°C until processed for Western blotting.
Western blotting and quantification
The proteins in sample buffer were denatured by 
keeping at 100°C for 3–5 min in a dry bath. About 1~5ug 
of histone proteins were separated in a 14% (w/v) SDS-
PAGE and transferred onto a nitrocellulose membrane 
(Bio-rad). After blocking the membrane with 5% 
(W/V) BSA in Tris-Buffered Saline Tween-20 (TBST), 
the membrane was incubated overnight with primary 
antibody, washed in TBST, incubated with Horseradish 
peroxidase (HRP) conjugated secondary antibody (anti-
rabbit IgG, Sigma; anti-mouse IgG, Upstate) at 1:5,000 
dilution in TBST, washed and carefully developed 
with ECL (Pierce). The following primary antibodies 
were used: H3(ab 1791, Abcam), H3K4me3(39159, 
Active Motif), H3R2me2(04-808, UBI), H3K27me3 
(39156, Active Motif), H3K79me3 (ab 2621, Abcam), 
H4K20me (ab 9051, Abcam), H3K56ac(07-677, UBI), 
H3K9me3(39161, Active Motif), H4K20me2(07-367, 
UBI), H4K16ac(39167, Active Motif), H3K18ac (ab 
1191, Abcam), H4R3me2(ab 5823, Abcam), H3K27ac 
(39685, Active Motif), H3K4me(ab 8895,Abcam), 
H3K4me2(07-030, UBI). The quality, especially 
the specificity of all antibodies was first verified 
experimentally by us (data not shown). The blot was 
scanned by using Gel Doc XR system (Bio-Rad) with a 
dynamic range of greater than 3 order of magnitude, and 
signal intensities were quantified using Image J (http://
rsb.info.nih.gov/ij/), a most popular image acquisition 
tool for accurately calculating area and pixel value, and 
normalized to values of total H3, which is widely used as 
a loading control to quantify the amount of modifications 
of histones.
Statistical analysis
Statistical analyses were performed using SPSS 
statistics software. One-way ANOVA was used to evaluate 
the p-value among comparisons, and then followed with 
a further post-hoc multiple comparisons between groups 
according to the equal variances assumed or not. Results 
were presented as group means± SEM. Each group has 3-5 
animals. Statistical significance was defined as p < 0.05.
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